(VIANEWS) – The NASDAQ opens in less than one hour and Castle Biosciences‘s pre-market value is already 5.24% up.
The last session, NASDAQ ended with Castle Biosciences (CSTL) sliding 3.56% to $20.05. NASDAQ slid 0.41% to $16,019.27, after two sequential sessions in a row of losses, on what was a somewhat down trend exchanging session.
About Castle Biosciences
Castle Biosciences, Inc., a molecular diagnostics company, provides testing solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus, uveal melanoma, and mental health conditions. It offers DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma; DecisionDx-SCC, a proprietary risk stratification GEP test for patients with cutaneous squamous cell carcinoma; MyPath Melanoma, a test used for patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a spatial omics test to predict future development of high-grade dysplasia and/or esophageal cancer in patients with non-dysplastic, indefinite dysplasia, or low-grade dysplasia Barrett's esophagus. In addition, the company provides DecisionDx-UM test, a proprietary risk stratification GEP test that predicts the risk of metastasis for patients with uveal melanoma; and IDgenetix, a pharmacogenomic test that helps guide drug treatment for major depressive disorder, schizophrenia, bipolar disorder, anxiety disorders, social phobia, obsessive-compulsive personality disorder, post-traumatic stress disorder, and attention deficit hyperactivity disorder. It offers its products to skin cancer, gastroenterology, and mental health markets. The company was incorporated in 2007 and is headquartered in Friendswood, Texas.
Earnings Per Share
As for profitability, Castle Biosciences has a trailing twelve months EPS of $-2.14.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -14.54%.
Earnings Before Interest, Taxes, Depreciation, and Amortization
Castle Biosciences’s EBITDA is 1.56.
More news about Castle Biosciences (CSTL).
